Sponsor
Rick W. Allen
Representative · R-GA
Representative · R-GA
The bill prioritizes transparency and reduced PBM conflicts to lower drug costs and improve plan decision‑making, but imposes compliance burdens and creates risks of cost‑shifting that could raise premiums or drug prices for some beneficiaries.
Patients with chronic conditions, hospitals, and beneficiaries (Medicare/Medicaid) may pay lower prescription drug costs because PBM kickbacks and opaque compensation would be restricted, improving affordability.
Covered health plans, plan fiduciaries, and beneficiaries would gain greater transparency and accountability—compensation must be characterized by economic substance and certain payments are presumed improper absent contemporaneous documentation—reducing conflicts of interest and helping plans select vendors based on net value.
Patients (especially those with chronic conditions) and public program beneficiaries could face higher drug prices if PBMs respond by shifting costs, changing contracting strategies, or losing negotiation leverage as a result of the restrictions.
Taxpayers, employers, and beneficiaries may see higher premiums or administrative fees because PBMs and plans will incur additional compliance and documentation costs to justify payments.
Small employers and some covered plans could lose access to legitimate third‑party brokers, consultants, or specialized services if the broad presumption discourages their use absent heavy contemporaneous paperwork, limiting expert support for plan decisions.
Based on analysis of 2 sections of legislative text.
Prohibits certain PBM and covered service provider payments to parties that contract with covered plans and requires compensation be judged by economic substance with documentation presumptions.
Official title: To amend section 408 of the Employee Retirement Income Security Act of 1974 to prohibit kickbacks to pharmacy benefit managers.
Introduced March 12, 2026 by Rick W. Allen · Last progress March 12, 2026
Prohibits certain compensation arrangements from pharmacy benefit managers (PBMs) and related service providers to parties that contract with employer-sponsored and other covered private health plans for pharmacy benefit management. It requires that compensation be judged by its economic substance (not by labels), creates a legal presumption that payments from covered service providers to brokers, consultants, advisors, or related entities are tied to prohibited activities unless contemporaneous written records show otherwise, and applies to plan years beginning after enactment.